NASDAQ: PIRS - Pieris Pharmaceuticals, Inc.

Lønnsomhet i seks måneder: +58.69%
Sektor: Healthcare

Kampanjeplan Pieris Pharmaceuticals, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.

flere detaljer
The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2015-04-13
ISIN US7207951036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.pieris.com
Цена ао 0.188
Prisendring per dag: 0% (13.6)
Prisendring per uke: 0% (13.6)
Prisendring per måned: -19.19% (16.83)
Prisendring over 3 måneder: -15.84% (16.16)
Prisendring over seks måneder: +58.69% (8.57)
Prisendring per år: +7 372.53% (0.182)
Prisendring over 3 år: +296.5% (3.43)
Prisendring over 5 år: +242.57% (3.97)
Prisendring over 10 år: 0% (13.6)
Prisendring siden begynnelsen av året: -15.53% (16.1)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0.3316 10
P/BV 0.5305 10
P/E 0 0
EV/EBITDA 0.2277 10
Total: 6.25

Effektivitet

Navn Betydning Karakter
ROA, % -63.45 0
ROE, % -91.72 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.9315 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -7.54 0
Lønnsomhet Ebitda, % -12.79 0
Lønnsomhet EPS, % 4546.31 10
Total: 2.2
Flere detaljer

Institusjoner Volum Dele, %
BVF Inc. 20609863 20.83
Lynx1 Capital Management Lp 9775849 9.88
Citadel Advisors Llc 1189887 1.2
Renaissance Technologies, LLC 1065007 1.08
Blackrock Inc. 1037747 1.05
Acadian Asset Management. LLC 962358 0.97
Vanguard Group Inc 907390 0.92
Geode Capital Management, LLC 761444 0.77
CM Management, LLC 750000 0.76
Northern Trust Corporation 243592 0.25



Veileder Stillingstittel Betaling Fødselsår
Mr. Stephen S. Yoder J.D. CEO, President & Director 744.13k 1976 (49 år)
Mr. Thomas Bures Senior VP, CFO & Treasurer 487.5k 1975 (50 år)
Maria Kelman Executive Director of Investor Relations N/A
Dr. Shane Olwill Ph.D. Senior VP & Chief Development Officer 463.91k 1976 (49 år)
Mr. Prompong Chaikul Chief Supply Chain Officer N/A 1987 (38 år)

Adresse: United States, Boston. MA, 225 Franklin Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.pieris.com